Targeting PDGFR, VEGFR, and FGFR to effectively suppress angiogenesis renders pazopanib and anlotinib valuable in the treatment of osteosarcoma,158 breast cancer,159 ovarian cancer,160 renal cancer,161 soft tissue sarcoma, and lung cancer.162. Here, KDR is linked to breast carcinoma.